OPTUS Pharmaceutical Statistics
Total Valuation
OPTUS Pharmaceutical has a market cap or net worth of KRW 88.36 billion. The enterprise value is 22.51 billion.
Market Cap | 88.36B |
Enterprise Value | 22.51B |
Important Dates
The last earnings date was Thursday, November 14, 2024.
Earnings Date | Nov 14, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
OPTUS Pharmaceutical has 16.15 million shares outstanding. The number of shares has decreased by -1.44% in one year.
Current Share Class | n/a |
Shares Outstanding | 16.15M |
Shares Change (YoY) | -1.44% |
Shares Change (QoQ) | +0.08% |
Owned by Insiders (%) | 0.80% |
Owned by Institutions (%) | 5.73% |
Float | 9.52M |
Valuation Ratios
The trailing PE ratio is 8.13.
PE Ratio | 8.13 |
Forward PE | n/a |
PS Ratio | 1.07 |
PB Ratio | 0.61 |
P/TBV Ratio | n/a |
P/FCF Ratio | 7.98 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.84, with an EV/FCF ratio of 2.03.
EV / Earnings | 2.20 |
EV / Sales | 0.29 |
EV / EBITDA | 1.84 |
EV / EBIT | 2.72 |
EV / FCF | 2.03 |
Financial Position
The company has a current ratio of 7.26, with a Debt / Equity ratio of 0.01.
Current Ratio | 7.26 |
Quick Ratio | 6.16 |
Debt / Equity | 0.01 |
Debt / EBITDA | 0.15 |
Debt / FCF | 0.16 |
Interest Coverage | 74.39 |
Financial Efficiency
Return on equity (ROE) is 7.71% and return on invested capital (ROIC) is 3.83%.
Return on Equity (ROE) | 7.71% |
Return on Assets (ROA) | 3.54% |
Return on Capital (ROIC) | 3.83% |
Revenue Per Employee | 489.25M |
Profits Per Employee | 64.45M |
Employee Count | 159 |
Asset Turnover | 0.53 |
Inventory Turnover | 2.67 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +7.28% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +7.28% |
50-Day Moving Average | 6,562.80 |
200-Day Moving Average | 6,502.00 |
Relative Strength Index (RSI) | 32.23 |
Average Volume (20 Days) | 82,062 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OPTUS Pharmaceutical had revenue of KRW 77.79 billion and earned 10.25 billion in profits. Earnings per share was 672.46.
Revenue | 77.79B |
Gross Profit | 43.02B |
Operating Income | 8.29B |
Pretax Income | 12.29B |
Net Income | 10.25B |
EBITDA | 12.25B |
EBIT | 8.29B |
Earnings Per Share (EPS) | 672.46 |
Balance Sheet
The company has 67.66 billion in cash and 1.81 billion in debt, giving a net cash position of 65.85 billion or 4,076.39 per share.
Cash & Cash Equivalents | 67.66B |
Total Debt | 1.81B |
Net Cash | 65.85B |
Net Cash Per Share | 4,076.39 |
Equity (Book Value) | 137.73B |
Book Value Per Share | 9,017.05 |
Working Capital | 79.83B |
Cash Flow
In the last 12 months, operating cash flow was 13.41 billion and capital expenditures -2.34 billion, giving a free cash flow of 11.07 billion.
Operating Cash Flow | 13.41B |
Capital Expenditures | -2.34B |
Free Cash Flow | 11.07B |
FCF Per Share | 685.59 |
Margins
Gross margin is 55.30%, with operating and profit margins of 10.65% and 13.17%.
Gross Margin | 55.30% |
Operating Margin | 10.65% |
Pretax Margin | 15.80% |
Profit Margin | 13.17% |
EBITDA Margin | 15.74% |
EBIT Margin | 10.65% |
FCF Margin | 14.24% |
Dividends & Yields
OPTUS Pharmaceutical does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 14.89% |
Buyback Yield | 1.44% |
Shareholder Yield | 1.44% |
Earnings Yield | 12.29% |
FCF Yield | 12.53% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
OPTUS Pharmaceutical has an Altman Z-Score of 5.91.
Altman Z-Score | 5.91 |
Piotroski F-Score | n/a |